Jefferies initiates Tempus AI stock with underperform rating

Jefferies initiated Tempus AI at Underperform with a $35 price target, implying 18% downside from $42.94 and adding to a stock that is already down 54% over the past six months. The firm highlighted unclear catalyst visibility, reimbursement risk, and competitive pressure across Tempus’s therapy selection, MRD, and data/applications businesses. Offset by ongoing partnership wins, Tempus remains unprofitable despite 83% revenue growth to $1.27 billion and a $245 million net loss over the last twelve months.

Analysis

TEM looks less like a broken story than a classic multiple de-rating in a market that is re-pricing reimbursement optionality. The core second-order risk is that its AI/data franchise has become more partner-dependent just as buyers are consolidating around a smaller set of validation and workflow standards; that raises the probability of price pressure even if top-line growth stays fast. The biggest loser is not necessarily TEM’s current revenue base, but its future bargaining power: once reference pricing is reset lower in one channel, it tends to bleed into adjacent products and weaken cross-sell economics.

PSNL is the cleaner relative winner on any path where in-house MRD investment matters, because it captures more convexity if the market rewards owned assay economics over partnered economics. GILD and MDT are incremental beneficiaries from the collaboration headlines, but the read-through is mostly strategic rather than financial: they gain access to a broader discovery stack without needing to own the AI infrastructure outright. That matters because pharma budgets are increasingly favoring flexible, outsourced analytics with short payback periods, while diagnostics platforms with weaker reimbursement moats face margin compression.

Catalyst timing is asymmetric: the bearish case can resolve over the next 1-3 quarters if reimbursement pressure, slower product monetization, or weaker opt-in conversions show up in reported KPIs. The bullish reversal requires either a clear reimbursement surprise, a credible path to margin inflection, or evidence that partnerships are driving durable recurring usage rather than one-off research spend. Consensus may be underestimating how quickly a high-growth, unprofitable story can re-rate when the market stops paying for TAM and starts paying for unit economics.

Key Decisions for Investors

• Short TEM on strength into analyst-ratings volatility; use a 1-3 month horizon with a tight stop above recent resistance, targeting a further 15-25% drawdown if reimbursement/margin concerns reassert.
• Prefer PSNL over TEM as a relative-value pair trade over the next 3-6 months: long PSNL / short TEM to express the view that owned MRD economics deserve a premium to partnership-heavy exposure.
• Buy out-of-the-money TEM puts 2-4 months out to capture downside from any reimbursement or guide-down shock; skew is likely cheaper than realized risk if the stock has stabilized after the initial de-rating.
• For event-driven exposure, hold GILD/MDT only as small tactical longs on partnership optionality; treat them as low-beta beneficiaries rather than core alpha names.